Clinical Trials Browser

INDUSTRY × Lymphoma × Rituximab × Clear all

NCT07015242 2026-03-11

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Phase 2 Recruiting

Lymphoma

NCT06084936 2026-03-03

GLOBRYTE

Phase 3 Recruiting

Lymphoma

NCT06191744 2026-03-03

EPCORE™FL-2

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06356129 2026-02-12

GOLSEEK-1

Phase 3 Active not recruiting

Lymphoma

NCT04384484 2026-01-26

LOTIS 5

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05737628 2026-01-16

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Phase 1 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin

NCT06425302 2026-01-08

GOLSEEK-2

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05951959 2025-10-21

TrAVeRse

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05409066 2025-07-28

EPCORE FL-1

Phase 3 Active not recruiting

549 enrolled 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04673617 2025-06-11

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin

NCT06790420 2025-05-31

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Infections, Lymphoma

NCT01974440 2025-05-25

SELENE

Phase 3 Completed

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase 1 Terminated

Lymphoma, Recurrence

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase 3 Completed

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05144009 2025-01-30

LOTIS-9

Phase 2 Terminated

41 enrolled 19 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05406401 2024-10-15

waveLINE-007

Phase 2 Active not recruiting

Lymphoma

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT02594384 2024-08-22

LAM-002A/NHL

Phase 1 Completed

62 enrolled 20 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Phase 1/2 Terminated

43 enrolled 15 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03934814 2024-07-01

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Phase 1 Completed

Lymphoma

NCT02031419 2024-01-18

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Phase 1 Terminated

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03900377 2023-11-24

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Phase 1/2 Completed

Lymphoma

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT02257567 2022-11-14

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

331 enrolled 81 charts 1 FDA

Lymphoma

NCT03189836 2021-10-11

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Phase 1 Terminated

Lymphoma, Recurrence

NCT01742988 2021-05-06

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Phase 1 Completed

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02605694 2021-03-17

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Phase 2 Withdrawn

Lymphoma

NCT02165397 2021-03-03

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Phase 3 Completed

181 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia

NCT02729896 2020-12-23

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

36 enrolled 22 charts

Lymphoma

NCT00551239 2020-10-19

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Phase 3 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01889069 2020-08-13

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Phase 3 Completed

159 enrolled 24 charts

Lymphoma

NCT00451178 2020-07-21

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Phase 2 Completed

101 enrolled 15 charts

Lymphoma

NCT02776813 2020-03-31

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Phase 1 Completed

Lymphoma, Recurrence

NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Phase 2 Terminated

81 enrolled 15 charts

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Phase 2 Terminated

24 enrolled 10 charts

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01232556 2019-01-08

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Phase 3 Terminated

338 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01453205 2018-03-12

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Completed

187 enrolled 21 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Phase 1/2 Completed

119 enrolled 60 charts

Lymphoma, Lymphoma, B-Cell

NCT00517049 2017-06-06

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT01421667 2016-11-28

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

176 enrolled 30 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00831597 2016-04-19

904

Phase 2 Completed

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Phase 2 Terminated

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

NCT01609010 2014-09-08

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Phase 3 Completed

313 enrolled 15 charts

Lymphoma

NCT00517699 2014-08-08

A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Phase 2 Terminated

5 enrolled 3 charts

Lymphoma

NCT01983761 2013-11-18

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Phase 1/2 Unknown

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

NCT01118845 2013-07-04

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Completed

63 enrolled 46 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating